Scholar Rock Holding Corporation - Common Stock (SRRK)

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

Scholar Rock invests heavily in its lead drug apitegromab, targeting a 2026 launch for spinal muscular atrophy despite a wider Q3 2025 loss.

Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten.

The biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects.

Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.

A pundit at an influential U.S. bank is quite bullish on the company's future.

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market.

Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug.